Curbstone Financial Management Corp Has $483,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Curbstone Financial Management Corp boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,266 shares of the medical equipment provider’s stock after purchasing an additional 140 shares during the quarter. Curbstone Financial Management Corp’s holdings in Zimmer Biomet were worth $483,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ZBH. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the fourth quarter valued at approximately $25,000. Menard Financial Group LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $30,000. Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $36,000. Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $39,000. Finally, OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price target on shares of Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating for the company in a report on Tuesday, May 6th. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Tuesday, May 6th. Morgan Stanley reduced their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. Finally, BTIG Research restated a “buy” rating on shares of Zimmer Biomet in a report on Monday, April 14th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $111.53.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $94.16 on Thursday. The stock has a market cap of $18.63 billion, a P/E ratio of 21.16, a P/E/G ratio of 1.95 and a beta of 0.72. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a fifty day moving average price of $96.94 and a two-hundred day moving average price of $103.82. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company’s revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.94 earnings per share. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet’s payout ratio is presently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.